| Entries |
| Document | Title | Date |
|---|
| 20080200394 | Treatment of Inflammatory Airway Disease - This invention relates to methods of treatment of inflammatory airway disease, and in particular to methods of treatment of asthma and chronic obstructive pulmonary disease. The invention is applicable to both allergic (atopic) and non-allergic (intrinsic) asthma. In one form the method comprises the step of administering an effective amount of a compound which has the ability to inhibit one or more functions of the T cell receptor (TCR) to a subject in need of such treatment, which is preferably a peptide whose sequence is derived from an invariant region of (a) the TCR | 08-21-2008 |
| 20080200395 | Treatment of cancer by a combination of non-ionizing radiation and androgen deprivation - A combined androgen deprivation and thermotherapy cancer treatment. For example, the combination can be used to treat prostate cancer. Chemical compounds, including a non-steroidal anti-androgen and/or an LH-RH agonist, such as androgen deprivation therapy (“ADT”), can be used in combination with application of non-ionizing radiation to treat cancer. The chemical compounds can be administered before, simultaneously with, and/or after the application of the non-ionizing radiation. When the ADT is applied before the application of the radiation, a reduction in cancer volume can be expected. In patients treated in such a manner, evidence of recurring cancer was not observed. | 08-21-2008 |
| 20080207523 | COMPOUNDS AS APTAMER-DIMERS AND THEIR USES IN DIAGNOSIS AND THERAPY - The object of the present invention is solved by compositions of peptide linkers and their use for synthesis and annealing of aptamer oligonucleotides in form of dimers. The present invention in particularly provides said compositions for the use as a diagnostic and/or therapeutic agent. | 08-28-2008 |
| 20080214470 | Pin1-Modulating Compounds and Methods of Use Thereof - The invention is directed to peptide modulators of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer or neurodegenerative disease. | 09-04-2008 |
| 20080221040 | Compositions and Methods for the Control of Mammary Cell Number - The present invention provides new methods and uses of peptides in effecting a reduction in mammary cell number. The discovery that these peptides reduce mammary cell number further enables the use of these peptides in the treatment of cancer where the peptides can be used to reduce cell number and accordingly reduce or prevent tumour development. The inventor has further shown that the peptides have specific utility in the treatment of breast cancer. | 09-11-2008 |
| 20080221041 | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension - The present invention relates to peptides which are highly biologically and pharmacologically active as therapeutic drug for the treatment of diseases related to hypertension, especially in medical interventions involving dilatation and remodeling of arterial blood vessels, either in the pulmonary or in the systemic circulation. The peptides which can be used according to the invention for the treatment of said diseases comprise at least one specific highly conservative amino acid residue sequence which seem to play an important role in connection with pulmonary and arteriolar hypertension events. It could be shown that the known naturally occurring peptides “vasoactive intestinal peptide (VIP)” and “pituitary adenylate cyclase-activating polypeptide (PACAP)”, having these specific sequences are potent drugs which can be successfully used for treatment of primary pulmonary hypertension (PPH), secondary pulmonary hypertension (SPH), and hypertension of the systemic circulation. Furthermore, the present invention discloses pharmaceutical compositions useful for treatment of PPH, SPH, and hypertension of the systemic circulation within said methods. | 09-11-2008 |
| 20080221042 | Alzheimer's disease-specific alterations of the ERK1/ERK2 Phosphorylation ratio-Alzheimer's disease-specific molecular biomarkers (ADSMB) - The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimer's cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's Disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's Disease, monitoring the progression of Alzheimer's Disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's Disease. The invention is also directed to kits containing reagents for the detection and diagnosis of the presence or absence of Alzheimer's Disease using the Alzheimer's Disease-specific molecular biomarkers disclosed herein. | 09-11-2008 |
| 20080227718 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE - The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of Aβ and antibodies binding to the same. | 09-18-2008 |
| 20080227719 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE - The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of Aβ and antibodies binding to the same. | 09-18-2008 |
| 20080227720 | Tumor cytotoxicity induced by modulators of the CXCR4 receptor - The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves (the modulators) such as that found in strains HIV-1, HIV-2, SIV, or FIV CXCR4-specific Gp 120 sequences or Nef proteins or sequences may be delivered to the mucosa or systemically. The mucosal means of application include oral, intranasal, ocular, intravaginal, rectal, and/or intraurethral administration in liquid or particulate form. | 09-18-2008 |
| 20080234203 | Use of Substances Having Oxytocin Antagonistic Properties - The present invention relates to uses of a substance having oxytocin antagonistic properties and to methods of treatment comprising administration of a pharmaceutically effective amount of said substance. | 09-25-2008 |
| 20080234204 | Methods for evaluating and implementing prostate disease treatments - Provide is a method for evaluating test agents as candidates for treating prostatic diseases, including benign prostatic hyperplasia (BPH) and androgen dependent and androgen independent prostate cancer. The method comprises providing a mouse comprising a human prostate primary xenograft, where the xenograft contains blood vessels that include human endothelial cells, initiating androgen deprivation in the mouse, administering to the mouse a test agent within a period of 1-7 days after initiating the androgen deprivation, and determining a reduction in human epithelial cells in the xenografts and/or a reduction in number of the endothelial cells or blood vessels in the xenograft. Also provided is a method for treating an individual for human prostate cancer or benign prostatic hyperplasia. The method comprises initiating androgen deprivation in the individual and administering to the individual an agent capable of inducing apoptosis of vascular endothelial cells within a period of 1-7 days of initiating androgen deprivation. | 09-25-2008 |
| 20080255053 | METHOD FOR THE THERAPEUTIC MANAGEMENT OF ENDOMETRIOSIS - The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to 12 weeks. According to another aspect of the present invention, the short term LH-RH treatment is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof. According to a further aspect of the present invention a pharmaceutical composition comprising an LHRH antagonist and one ore more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof are provided. | 10-16-2008 |
| 20080255054 | STERILE SUSPENSIONS OF SLIGHTLY SOLUBLE BASIC PEPTIDE COMPLEXES AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM - The invention provides sterile suspensions and sterile lyophilizates of slightly soluble basic peptide complexes, and pharmaceutical formulations comprising them. The provided sterile suspensions, sterile lyophilizates and pharmaceutical formulations comprising them are particularly suitable for use in a parenteral dosage form as medicaments for the treatment and prophylaxis of diseases and pathological states in mammals, especially in humans. | 10-16-2008 |
| 20080269138 | Polyamides with tail structures - The present invention relates to polyamides with a tail comprising a linker and an end-group. A preferred end-group is isophthalic acid and derivatives thereof. Polyamides of the invention are capable of entering the nucleus of cells. Polyamides of the invention are capable of selectively binding DNA. The invention also relates to methods of using the polyamides in therapy and research. | 10-30-2008 |
| 20080269139 | FGF-5 Supported and Binding Peptides - The present invention provides peptides and supported peptides that bind to FGF-5. | 10-30-2008 |
| 20080274980 | MACROMONOMERS AND HYDROGEL SYSTEMS USING NATIVE CHEMICAL LIGATION, AND THEIR METHODS OF PREPARATION - The present invention provides novel biocompatible macromonomers, hydrogels, methods of synthesis and methods of use thereof. The biocompatible hydrogels of the present invention are prepared using native chemical ligation (NCL), in which a thioester readily reacts with a N-terminal thiol (cysteine) through transesterification and rearrangement to form an amide bond through a five-member ring intermediate. | 11-06-2008 |
| 20080287368 | Methods and Compositions For the Prevention and Treatment of Kidney Disease - The invention provides compositions for preventing or treating kidney disease comprising vitamin E, vitamin C, and a carotenoid and methods for preventing and treating kidney disease comprising administering such compositions to an animal susceptible to or suffering from kidney disease. In a preferred embodiment, the composition is admixed with one or more food ingredients to produce a food composition useful for preventing or treating kidney disease. | 11-20-2008 |
| 20080306008 | Peptides for Use in the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 12-11-2008 |
| 20080312155 | Metastin Derivatives and Use Thereof - The invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, etc.). By modifying the constituent amino acids of metastin with specific modifying groups, metastin derivatives having more improved blood stability, etc. than native metastin and showing excellent cancer metastasis suppressing activity or cancer growth suppressing activity have been found. Furthermore, it has been found that these metastin derivatives exhibit effects of suppressing gonadotropic hormone secretion, suppressing sex hormone secretion, etc., which are wholly different from the effects heretofore known. | 12-18-2008 |
| 20080312156 | In-Situ Crosslinkable Elastin-Like Polypeptides for Defect Filling in Cartilaginous Tissue Repair - Defects in a cartilaginous tissue are filled by: (a) mixing (i) a first reagent composition preferably comprising an amine-free hydroxyalkyl (preferably hydroxymethyl) phosphine crosslinking agent with (ii) a second reagent composition comprising a bioelastic polymer, the bioelastic polymer preferably comprising elastomeric units, the elastomeric units preferably selected from the group consisting of bioelastic pentapeptides, tetrapeptides, and nonapeptides; to produce a therapeutic composition; and then (b) administering the therapeutic composition to the cargilagenous tissue. Compositions and kits for carrying out the method are also described. | 12-18-2008 |
| 20080312157 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 12-18-2008 |
| 20080318869 | Method to Promote Wound Healing - Wound healing is impaired in irradiated animals. Substance P and its active analogs promote wound healing in irradiated animals. Substance P and its analogs can be used to treat animals irradiated by a nuclear weapon, a nuclear accident, or a therapeutic regimen, for example. Wounds which are susceptible to such treatment include surgical wounds, weapons wounds, disease-caused wounds, bed sores, diabetic ulcers, etc. | 12-25-2008 |
| 20080318870 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 12-25-2008 |
| 20090005318 | CONTROLLED RELEASE COMPOSITION AND METHOD OF PRODUCING THE SAME - A controlled release composition containing a physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. | 01-01-2009 |
| 20090012004 | HLA binding peptides and their uses - The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen. The immunogenic peptide compositions of the present invention comprise immunogenic peptides having an HLA binding motif, where the peptide is from a target antigen. Target antigens of the present invention include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e.g., MAGE-1), human immunodeficiency virus (HIV) antigens, human papilloma virus (HPV) antigens, Lassa virus, | 01-08-2009 |
| 20090018084 | METHODS OF RESTORING COGNITIVE ABILITY USING NON-PEPTIDIC COMPOUNDS - Disclosed are methods of enhancing cognitive impairment in a patient wherein the cognitive impairment is due to ADDL neurotoxicity. The methods employ non-peptidic compounds having a molecular weight of less than 1000 and which can antagonize against formation of neurotoxic ADDLs from Aβ | 01-15-2009 |
| 20090023661 | Use of Antagonists of the Bradykinin B2 Receptor for the Treatment of Osteoarthrosis - Peptides having bradykinin-antagonistic action are suitable for the production of pharmaceuticals for the prophylaxis and therapy of diseases in whose course an increased activity of matrix metalloproteinases is involved. These include diseases such as degenerative joint diseases, for example osteoarthrosis, spondylosis and chondroporosis after joint trauma or relatively long immobilization of a joint after meniscus or patella injuries or torn ligaments. The invention therefore relates to the use of a compound of the formula I, | 01-22-2009 |
| 20090029924 | Targeting Host Proteinases as a Therapeutic Strategy Against Viral and Bacterial Pathogens - Disclosed are compositions and methods for preventing or reducing harm resulting from pathogen infection. For example, disclosed are peptides that inhibit the processing of toxins normally cleaved by proprotein convertase enzymes. | 01-29-2009 |
| 20090036384 | INCREASING PREGNANCY RATES - The invention relates to a stable formulation for controlling oestrus in a subject. The formulation comprises Gonadotrophin Releasing Hormone or an acceptable salt or analogue thereof, progesterone or an analogue thereof, and an acceptable carrier. | 02-05-2009 |
| 20090048178 | LPS OR LIPID A BINDING AGENT AND NOVEL PEPTIDE - A lipopolysaccharide (LPS) and/or lipid A binding agent is provided. The LPS and/or lipid A binding agent contains an LPS and/or lipid A binding peptide, such as a peptide comprising an amino acid sequence of XYSSS (X=K, R, or H), or a derivative thereof, as an active ingredient. The LPS and/or lipid A binding agent is useful as, for example, an LPS and/or lipid A neutralizing agent or an LPS and/or lipid A removing agent. | 02-19-2009 |
| 20090048179 | USE OF 5-PHOSPHODIESTERASE INHIBITORS TO ENHANCE THE PERMEABILITY OF THE BLOOD-BRAIN BARRIER OF ABNORMAL BRAIN TISSUE AND THE BLOOD-TUMOR BARRIER - This invention relates to methods and kits for enhancing the permeability of the blood-brain barrier of abnormal brain tissue or the blood-tumor barrier. Particularly, methods comprising the administration of 5-phosphodiesterase inhibitors, such as sildenafil and vardenafil, to selectively enhance the permeability of the blood-brain barrier of abnormal brain tissue or the blood-tumor barrier are described. This selective enhancement allows for selective delivery of therapeutic agents or imaging to treat the abnormal brain tissue or a tumor, including brain tumors and non-central nervous system tumors. | 02-19-2009 |
| 20090048180 | Sustained-release preparation - A sustained-release preparation which comprises a physiologically active peptide of general formula | 02-19-2009 |
| 20090054345 | Template-Fixed Beta-Hairpin Peptidomimetics With Protease Inhibitory Activity - Templates-fixed β-hairpin peptidomimetics of the general formulae (I), wherein Z is a chain of 11α-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or Pro(4NHCOPhe), or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to inhibit proteases, in particular serine proteases, especially Cathepsin G or Elastase or Tryptase. These β-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy. | 02-26-2009 |
| 20090054346 | ELASTIN PRODUCTION-ENHANCING AGENTS - An objective of the present invention is to provide novel useful elastin production-enhancing agents that have a remarkable ability to enhance elastin production. The present invention provides elastin production-enhancing agents that include at least one component selected from the group consisting of the peptide Leu-Glu-His-Ala (formula I; SEQ ID NO:1), derivatives of the peptide, and salts thereof. The present invention also provides elastin production-enhancing agents that include at least one component selected from the group consisting of peptides which include a conservative substitution, deletion, and/or addition of one or more amino acids in the amino acid sequence of formula I that retain an ability to enhance elastin production in cells; derivatives of such peptides; and salts thereof. | 02-26-2009 |
| 20090054347 | KININ B1 RECEPTOR PEPTIDE AGONISTS AND USES THEREOF - The present invention provides for novel kinin B1 receptors peptide agonists of formula (I) having very good to excellent affinities and selectivity for the B | 02-26-2009 |
| 20090054348 | BI-DENTATE COMPOUNDS AS KINASE INHIBITORS - The present invention provides compound having the general structure A or pharmaceutically acceptable salts thereof: | 02-26-2009 |
| 20090062208 | Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-PKC inhibitor - Methods for maintaining the integrity of the blood-brain barrier are described. Compounds that act to inhibit the action of the delta isozyme of protein kinase C (PKC) to prevent disruption of the blood-brain barrier in hypertensive subjects are described, to, in one embodiment, decrease the likelihood of hypertension-induced stroke or hypertension-induced encephalopathy. | 03-05-2009 |
| 20090062209 | METHODS OF USE OF EPSILON INHIBITOR COMPOUNDS FOR THE ATTENUATION OF PAIN - The disclosure herein relates to modified εPKC inhibitory peptides, methods of generating such peptides, and method for using εPKC inhibitory peptides for the treatment of pain. | 03-05-2009 |
| 20090069244 | Mutants of lactoferrin - The invention relates to field of biochemistry, molecular biology as well as medicinal chemistry. More in specific, the invention relates to polypeptides derived from human lactoferrin and their use in therapeutic or prophylactic treatment. The invention provides a polypeptide comprising a mutant of the amino acid sequence RRRRSVQWC (SEQ ID NO:2), which mutation comprising polypeptide has comparable antimicrobial activity against at least one micro-organism if compared to a reference polypeptide comprising the amino acid sequence RRRRSVQWC (SEQ ID NO:2). | 03-12-2009 |
| 20090069245 | GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF - The present invention provides novel compounds that have been demonstrated to be modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, iso forms and variants thereof). These compounds are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders. | 03-12-2009 |
| 20090075900 | Therapeutic agent for motor neuron disease - An object of the present invention is to provide an agent effective for the treatment and/or prevention of motor neuron disease such as amyotrophic lateral sclerosis (ALS). The present invention provides a therapeutic and/or preventive agent for motor neuron disease comprising the following oligopeptide shown in any of (a) to (c) or a pharmaceutically acceptable salt thereof as an active ingredient: (a) an oligopeptide consisting of the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1); (b) an oligopeptide consisting of an amino acid sequence having a deletion, substitution, insertion, or addition of one or several amino acids in Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death caused by a mutant superoxide dismutase-1 gene; and (c) a modified oligopeptide from the oligopeptide (a) or (b). | 03-19-2009 |
| 20090075901 | PEPTIDES FOR ACTIVATION AND INHIBITION OF DELTAPKC - Peptides able to inhibit or activate the translocation or function of δPKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as well as methods for screening test compounds for δPKC-selective agonists and antagonists. | 03-19-2009 |
| 20090075902 | INHIBITING THE SIGNS OF AGING BY INHIBITING NF-KAPPA B ACTIVATION - The present invention relates to methods and compositions for reducing and/or delaying one or more signs of aging which comprise inhibiting NF-kappa B activation. It is based, at least in part, on the discovery that a peptide which inhibits IKK-β interaction with NEMO, linked to a transducing peptide, inhibits the development of various indicia of senescence in a murine model of aging, Ercc1 | 03-19-2009 |
| 20090075903 | METHOD OF USING SUBSTANCE P ANALOGS FOR TREATMENT AMELIORATION OF MYELODYSPLASTIC SYNDROME - Myelodysplastic syndromes can be treated or ameliorated by the administration of substance P analogs as disclosed herein. | 03-19-2009 |
| 20090099090 | HLA-A24-RESTRICTED CANCER ANTIGEN PEPTIDES - HLA-A24-restricted peptides derived from WT1 which have an activity to induce CTLs in vivo, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. The cancer vaccines of the present invention may be used to treat many cancer patients. | 04-16-2009 |
| 20090099091 | Oligopeptide Tyrosinase Inhibitors and Uses Thereof - Disclosed are peptides that inhibit the enzymatic activity of tyrosinase, as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. Peptide sequences disclosed include KFEKKFEK and YRSRKYSSWY. | 04-16-2009 |
| 20090099092 | METHODS FOR STIMULATING FIBROBLAST PROLIFERATION USING SUBSTANCE P ANALOGS - Provided herein are methods and compositions for stimulating or promoting fibroblast proliferation. In one embodiment, provided herein are methods and compositions for promoting or enhancing wound healing. | 04-16-2009 |
| 20090105153 | Gonadotropin Releasing Hormone Antagonists - Antagonistic peptides of GnRH having improved water solubility are disclosed. These peptides are capable of suppressing serum testosterone levels in vivo to chemical castration levels of ≦0.5 ng/ml. Stable, filter sterilizable, non-gelling solutions containing the GnRH antagonists at least at levels typically used in sustained release formulations also are disclosed, as is a method of increasing the solubility of GnRH antagonist in a polymer containing dispersed phase, which method comprises addition of an acid to the dispersed phase. | 04-23-2009 |
| 20090105154 | COMPOSITION FOR PREVENTION OR TREATMENT OF GASTROINTESTINAL DAMAGE - Disclosed herein are a composition for prevention or treatment of gastrointestinal damage comprising Substance-P as an active ingredient, a use of Substance-P for the preparation of a medicament for prevention or treatment of gastrointestinal damage, and a method for prevention or treatment of gastrointestinal damage comprising administering a therapeutically effective amount of Substance-P to a mammal. | 04-23-2009 |
| 20090118195 | Molecules Which Promote Hematopoiesis - The invention relates to supravalent peptide compounds depicting an enhanced efficacy. Supravalent compounds comprise several at least bivalent peptide units that bind to a receptor target and are connected to a large polymeric carrier unit. | 05-07-2009 |
| 20090124556 | Peptides Exhibiting Efficacies of Improvement in Skin Conditions or Treatment of Periodental Diseases - The present invention relates to a composition for improving a skin condition or treating a periodontal disease, which comprises as an active ingredient a basic fibroblast growth factor-derived peptide. The peptides of this invention exhibit superior efficacies and much better stability and skin permeation than natural-occurring bFGF. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on improvement in skin conditions and treatment of periodontal diseases. In addition, the peptides of this invention can be advantageously applied to pharmaceutical compositions, cosmetics, tooth-paste and compositions for mouth cleaning and caring. | 05-14-2009 |
| 20090131321 | Method of reducing injury to mammalian cells - A method of inhibiting the binding between N-methyl-D-aspartate receptors and neuronal proteins in a neuron the method comprising administering to the neuron an effective inhibiting amount of a peptide replacement agent for the NMDA receptor or neuronal protein interaction domain that effect said inhibition of the NMDA receptor neuronal protein. The method is of value in reducing the damaging effect of injury to mammalian cells. Postsynaptic density-95 protein (PSD-95) couples neuronal N-methyl-D-aspartate receptors (NMDARs) to pathways mediating excitotoxicity and ischemic brain damage. This coupling was disrupted by transducing neurons with peptides that bind to modular domains on either side of the PSD-95/NMDAR interaction complex. This treatment attenuated downstream NMDAR signaling without blocking NMDAR activity, protected cultured cortical neurons from excitotoxic insults and dramatically reduced cerebral infarction volume in rats subjected to transient focal cerebral ischemia. The treatment was effective when applied either before, or one hour after, the onset of excitotoxicity in vitro and cerebral ischemia in vivo. This approach prevents negative consequences associated with blocking NMDAR activity and constitutes practical therapy for stroke. | 05-21-2009 |
| 20090137484 | Neuronal Network-Interacting Peptide - The invention provides a method for treating a neuronal-associated condition comprising administering a composition comprising a therapeutically effective amount of a polypeptide or a biologically active fragment thereof, the polypeptide or the fragment thereof capable of modulating the interaction between Nogo-ephrinB and/or Nogo-Grb4 third SH3 domain. There are also provided isolated polypeptide or fragment thereof. The invention further provides a method of screening a compound for effectiveness as an agonist or as an antagonist of the polypeptide or fragment thereof according to the invention. | 05-28-2009 |
| 20090137485 | Antigens Targeted by Pathogenic T Cells in Type 1 Diabetes and Uses Thereof - Provided are polypeptides that are capable of binding a human HLA-A2 MHC class I molecule. Kits comprising these polypeptides in a container are also provided. Further provided are methods for determining whether a mammal is at risk for or has type 1 diabetes. Additionally provided are methods of preventing a CD8 | 05-28-2009 |
| 20090137492 | METHOD TO REDUCE THE RISK AND/OR SEVERITY OF ANTHRAX INFECTION - Neuropeptides are used to treat mammals who have been exposed to or who are suspected of having been exposed to spores of | 05-28-2009 |
| 20090149393 | Novel Proteins Within The Type E Botulinum Neurotoxin Complex - The invention features a polypeptide complex synthesized by bacteria of the genus | 06-11-2009 |
| 20090156506 | USE OF VEGF-D IN THE DIAGNOSIS OF LYMPHANGIOLEIOMYOMATOSIS (LAM) DISEASE - Described herein are methods of diagnosing lymphangioleiomyomatosis (LAM) that permits differentiating LAM from another lung disorder. Methods of treatment are also provided. | 06-18-2009 |
| 20090170782 | Gnrh Analogue Formulations - The present invention relates to compositions forming a low viscosity mixture of: a) at least one diacyl glycerol; b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one GnRH analogue; Wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, pre-filled administration devices and kits containing the formulations. | 07-02-2009 |
| 20090176712 | Peptides with Efficacy in Rescuing Melanocortin-4 Receptor Polymorphic Agonist Signaling - Disclosed are novel ligands based on an AGRP template that can rescue endogenous melanocortin agonist and/or antagonist dysfunction at MCR polymorphisms. In particular, the present invention provides novel synthetic ligands based on AGRP templates that can rescue endogenous melanocortin agonist dysfunction at MC4R polymorphisms to treat children and adults with these mutations and increase their quality of life. | 07-09-2009 |
| 20090176713 | Co-Administration of an Agent Linked to an Internalization Peptide with an Anti-Inflammatory - The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension. | 07-09-2009 |
| 20090192092 | Neuropeptides and Their Use for Pest Control - The present invention discloses novel pest control compounds comprising NPF polypeptides and methods for using such compounds in the control of pests. | 07-30-2009 |
| 20090197812 | Peptides for Inhibiting Transglutaminase - Disclosed herein are transglutaminase peptide inhibitors which have inhibitory activity against transglutaminase, and a pharmaceutical composition comprising one of them as an active ingredient. The inhibitors or the composition is useful in the prevention and treatment of various diseases caused by aberrant transglutaminase activation, including inflammatory diseases and cancers. Also, methods for treating various inflammatory diseases and cancers and for preparing mutant peptides capable of inhibiting transglutaminase are also disclosed. | 08-06-2009 |
| 20090197813 | Methods for treating FSH related conditions with GnRH antagonists - Methods for treating FSH related conditions, such as prostatic intraepithelial neoplasia, pedophilia, infertility, or vaginal bleeding, with GnRH antagonists are disclosed. The methods of the invention generally feature administering to a subject a GnRH antagonist suitable for in vivo administration and able to reduce both plasma FSH and LH levels in a subject, in an amount or in a formulation effective to reduce plasma FSH levels in the subject to a symptom alleviating level. In vitro fertilization and male contraceptive methods are also provided. | 08-06-2009 |
| 20090203621 | Tripeptides that Down Regulate the Activity of Plasma Membrane transporters Including Sodium-D-Glucose Cotransporter Sglt1 - The present invention relates to the use of a regulatory protein RS1 fragment or a nucleic acid molecule encoding said regulatory protein RS1 fragment for the preparation of a pharmaceutical composition for the amelioration, prevention and/or treatment of a metabolic disease or a secondary disorder caused by a (pathological) modification of homeostasis, wherein said RS1 fragment is characterized in comprising at least the amino acid sequence Q-C-P (Glutamine-Cysteine-Proline) or derivatives thereof. Furthermore, the present invention relates to a method for the amelioration, prevention and/or treatment of a metabolic disease or a secondary disorder caused by a (pathological) modification of homeostasis, said method comprising administering to a patient in need of such amelioration, prevention and/or treatment a pharmaceutically active amount of a regulatory protein RS1 fragment or a nucleic acid molecule encoding a regulatory protein RS1 fragment, wherein said RS1 fragment is characterized in comprising at least the amino acid sequence Q-C-P (Glutamine-Cysteine-Proline) or derivatives thereof. Moreover, the present invention relates to the use of a regulatory protein RS1 fragment or a nucleic acid molecule encoding said regulatory protein RS1 fragment for the preparation of food and/or food supplements. | 08-13-2009 |
| 20090203622 | METHOD OF TREATING METASTATIC STAGE PROSTATE CANCER - The invention provides methods and dosing regimens for treating metastatic stage prostate cancer in a subject using degarelix, as well as related methods of using degarelix in a subject identified as having metastatic stage prostate cancer, and methods of using degarelix to prevent or delay the progression of locally advanced prostate cancer. | 08-13-2009 |
| 20090203623 | METHOD OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST - The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. | 08-13-2009 |
| 20090203624 | ALPHA-FETOPROTEIN PEPTIDES - The invention relates to compounds that include peptides that inhibit estrogen receptor dependent cell proliferation. The compounds of the invention are useful for treating cell proliferative disorders or physiological conditions characterized by undesirable or unwanted estrogen induced cell proliferation, including breast cancer. | 08-13-2009 |
| 20090203625 | Phage Display Selection of Anti Fungal Peptides - A method for the identification of peptides having an affinity for the surface of fungi is provided as is a method for the identification of peptides capable of affecting the development of a fungus. Also provided are compositions containing peptides identified using the method of the present invention. In addition, isolated polynucleotides, vectors, expression cassettes and transformed cells capable of expressing peptides identified by the method of the present invention are provided. | 08-13-2009 |
| 20090215699 | Pharmaceutically Active Antiviral Peptides - The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects. | 08-27-2009 |
| 20090215700 | Metastin derivatives and use thereof - The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotropic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). | 08-27-2009 |
| 20090221510 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES - The present invention relates to novel uses of peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to methods of using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production, including chemotherapy induced anemia. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided. Also provided are kits and articles of manufacture comprising such compounds. | 09-03-2009 |
| 20090221511 | TRPV1 + SENSORY NEURONS CONTROL OF BETA-CELL STRESS AND ISLET INFLAMMATION IN DIABETES - A process is disclosed for controlling inflammatory tissue access through release of neuropeptides, such as substance P (sP), to insulin-responsive sensory neurons, whereby simultaneous control of insulin sensitivity/resistance is manifested. In models of Type 1 and Type 2 diabetes, sensory afferents, in particular TRPV1, have fundamental roles in insulin/glucose homeostasis, islet physiology and autoimmune tissue inflammation. By manipulation of the TRPV1 neuro-β-cell circuit or enhancement of pancreatic sP levels, normalization of insulin resistance, clearance of inflammation and prevention of both Type 1 and Type 2 diabetes is realized. | 09-03-2009 |
| 20090239806 | GLYPICAN-3 (GPC3)-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES USEFUL FOR HLA-A2-POSITIVE PATIENTS AND PHARMACEUTICAL COMPRISING THE SAME - It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B):
| 09-24-2009 |
| 20090253636 | Novel Antifungal Agent - It is intended to provide a novel peptide which can exert higher antifungal effect also on a patient whose organ function is impaired with no side effect problems. The peptide comprises the following amino acid sequence: (1) SEQ ID NO:1: Lys-Arg-Leu-Phe-Arg-Arg-Trp-Gln-Trp-Arg-Tyr, (2) SEQ ID NO:2: Arg-Arg-Trp-Gln-Trp-Arg-Met-Lys-Lys-Tyr, (3) SEQ ID NO:3: Lys-Arg-Trp-Gln-TTp-Arg-Leu-Tyr, or (4) SEQ ID NO:4: Lys-Arg-Leu-Phe-Lys-Tyr, an antifungal agent comprising the peptide, a composition having a fungicidal and/or growth inhibitory action against fungus containing an effective amount of the peptide as an active ingredient, a medical apparatus/device which contains the peptide, whereby a fungicidal action is conferred, and a fungicidal and/or growth inhibiting method against fungus comprising administering the peptide and the like. | 10-08-2009 |
| 20090264371 | ANTIPROLIFERATIVE PEPTIDES AND ANTIBODIES FOR THEIR DETECTION - The present invention relates to developmental peptides and peptidomimetics thereof, which may be used therapeutically to inhibit abnormal cell proliferation of damaged cells, including cancer cells or virally infected cells. In one embodiment, a seven to eleven amino acid developmental peptide and methods of using the same is provided. | 10-22-2009 |
| 20090270335 | COLLYRIUM FOR DRY EYE - A composition for treating dry eye includes eledoisin formulated in an ester form and a phospholipid formulated in a micellar form. | 10-29-2009 |
| 20090275522 | Novel Compounds - The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification. | 11-05-2009 |
| 20090281042 | COMPOSITIONS AND METHODS USING SAME FOR THE DETECTION OF VIRUSES - An isolated peptide is provided. The isolated peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46 and 47, said amino acid sequence being no more than 14 amino acids in length. Also provided are compositions which comprise the peptides and use of same in the detection of viruses. | 11-12-2009 |
| 20090281043 | TUMOR ANTIGEN BASED ON PRODUCTS OF THE TUMOR SUPPRESSOR GENE WT1 - A tumor antigen that comprises, as an active ingredient, a product of the Wilms' tumor suppressor gene WT1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising said antigen. | 11-12-2009 |
| 20090286744 | Treatment of asthma - Substance P or its analogs are useful for treating asthma. The active agents can be administered orally, intravenously, intramuscularly, intranasally, topically. Disease severity is reduced by substance P treatment. | 11-19-2009 |
| 20090286745 | INHIBITION OF ALPHA-SYNUCLEIN AGGREGATION - This invention relates to the inhibition of alpha-synuclein aggregation using peptidyl compounds which are retroenantiomers of the alpha-synuclein sequence, in particular retroenantiomers of sequences in the regions between residues 1 to 60 or residues 61 to 96. Peptidyl compounds of the invention may optionally be coupled to doperminergic targeting moieties and/or blood brain barrier transport moieties and may be useful in the treatment of alpha-synucleinopathies such as Parkinson's disease. | 11-19-2009 |
| 20090286746 | Small Survival-Promoting/Immunomodulatory Peptide for Treatment of Brain Damage, Neurodegenerative Disorders, and Inflammatory Disorders - A synthetic peptide sequence demonstrating neuroprotective and anti-inflammatory functions is disclosed. Methods of use for the synthetic peptide are also provided. | 11-19-2009 |
| 20090291900 | METHODS FOR TREATMENT OF HEADACHES BY ADMINISTRATION OF OXYTOCIN - The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia. | 11-26-2009 |
| 20090312264 | Squamous Cell Carcinoma Antigen-Derived Peptide Binding to HLA-A24 Molecule - Provided is a squamous cell carcinoma antigen derived peptide which is capable of binding to an HLA-A24 molecule and recognized by the cellular immune system, and a pharmaceutical composition comprising said peptide for the treatment or prevention of squamous cell carcinoma. | 12-17-2009 |
| 20090312265 | NOVEL ANTIMICROBIAL PEPTIDES AND USE THEREOF - The invention relates to a molecule comprising at least the amino acid sequence K X K X | 12-17-2009 |
| 20090318365 | METASTIN DERIVATIVES AND USE THEREOF - The present invention provides a metastin derivative in which the amino acids comprising metastin were modified by alternative chemical substituents resulting in metastin derivatives, having excellent blood stability and exhibiting cancer metastasis inhibiting action or cancer growth inhibiting action. | 12-24-2009 |
| 20090325885 | COMPOSITION FOR ACCELERATION OF TYPE I COLLAGEN PRODUCTION - It is an object of the present invention to provide a composition for promoting the production of type I collagen by human skin fibroblasts, and the present invention relates to a composition for promoting type I collagen production containing silybin and a peptide that promotes collagen production (peptide having an amino acid sequence of Gly-Pro-Hyp, Gly-His-Lys, Lys-Thr-Thr-Lys-Ser or Gly-Glu-Pro-Arg). | 12-31-2009 |
| 20090325886 | WT1 MODIFIED PEPTIDE - The present invention discloses a cancer antigen peptide comprising the following amino acid sequence: Cys Tyr Thr Trp Asn Gln Met Asn Leu (Sequence ID No. 3), a cancer vaccine having this for its active ingredient, and a DNA vaccine having for its active ingredient DNA that codes for this peptide. | 12-31-2009 |
| 20100004180 | Agents for the Detection and Modulation of B-Cells and Antibodies - The present invention relates to the identification and use of peptide and peptide analogs that represent epitopes for naturally-occurring antibodies (Nabs). These epitopes may be used to monitor the degree of autoimmunity in an organism, as well as to modulate the activity of B-cells producing Nabs. | 01-07-2010 |
| 20100004181 | COMBINATION COMPRISING N-(3-METHOXY-5-METHYLPYRAZIN-2-YL)-2-(4-(1,3,4-OXADIAZOL-2-YL)PHENYL) PYRIDINE-3-SULPHONAMIDE AND AN LHRH ANALOGUE AND/OR A BISPHOSPHONATE - A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, and an LHRH analogue and/or a bisphosphonate is described. | 01-07-2010 |
| 20100009923 | Antigens Targeted by Pathogenic Al4 T Cells in Type 1 Diabetes and Uses Thereof - Provided are oligopeptide antigens to A14-like T cells, and mouse proteins comprising those antigens. The oligopeptide antigens comprise the amino acid sequence XX(I/D/F/L)ENY(I/L)(E/W/Y)(L/M) or VMLENYTHL. Additionally provided are methods for treating a mammal having or at risk for type 1 diabetes using these antigens, or compounds which reduce or eliminate expression of these antigens. Kits comprising these antigens, and methods for determining whether a mammal is at risk for or has type 1 diabetes are also provided. | 01-14-2010 |
| 20100016240 | FACILITATING CELLS AND DIABETES AND METHODS RELATED THERETO - This disclosure describes methods of screening for compounds that increase the number of p-preDCs and/or Tregs. | 01-21-2010 |
| 20100016241 | METHODS AND COMPOSITIONS FOR INHIBITING C-MET DIMERIZATION AND ACTIVATION - The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating c-met dimerization and/or binding of ligand to c-met using a c-met antagonist that disrupts c-met multimerization. | 01-21-2010 |
| 20100022457 | Sustained release glp-1 receptor modulators - The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation. | 01-28-2010 |
| 20100029573 | Tumor-associated peptides that bind to mhc-molecules - The invention relates to a tumor-associated peptide with an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 from the attached sequence protocol, the peptide being capable of binding to a molecule of the human major histocompatibility complex (MHC) class I. The invention further relates to the use of the peptides for preparation of a drug and for the treatment of tumor diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described comprising at least one of the peptides. | 02-04-2010 |
| 20100035822 | PROLINE-RICH PEPTIDES, PHARMACEUTICAL COMPOSITION, USE OF ONE OR MORE PEPTIDES AND METHOD OF TREATMENT - The present invention provides oligopeptides with amino acid sequences comprised in set forth in SEQ ID NO 1 to 18, capable of binding to diverse targets, generating increase and sustenance to nitric oxide (NO) production in mammalian cells, potentiate the argininosuccinate synthase activity of animal cells and/or increase the intracellular bivalent calcium ion in animal cells. Also disclosed are pharmaceutical compositions of one or more peptides described in the present invention. The invention further relates to the use of these peptides. | 02-11-2010 |
| 20100062986 | METHOD TO TREAT BLOOD CELL DEPLETION - Neuropeptides are used to treat mammals which have depletion of count of one or more blood cell types. Intramuscular administration or administration via inhalation causes the blood cell count to increase. | 03-11-2010 |
| 20100075909 | PEPTIDE - The present invention relates to a peptide that is derived from a milk protein and has an antioxidative effect, an antioxidant that includes the peptide as an active ingredient, and an antioxidative food, drink, or feed that includes the peptide. The present invention also relates to a peptide that is derived from a milk protein and has an adiponectin production promotion effect, an adiponectin production promoter that includes the peptide as an active ingredient, and an adiponectin production promotion food, drink, or feed that includes the peptide. The present invention further relates to a blood adiponectin level increase promotion and/or decrease inhibition agent that includes a component contained in cheese as an active ingredient, and a blood adiponectin level increase promotion and/or decrease inhibition food or drink that includes a component contained in cheese. The present invention to the peptide that consists of an amino acid sequence shown by His-Pro-Ile-Lys-His-Gln-Gly-Leu-Pro-Gln (1), His-Pro-Ile-Lys (2) or His-Gln-Gly-Leu-Pro-Gln (3), and has an antioxidative effect. | 03-25-2010 |
| 20100093637 | PEPTIDES AND USE THEREOF - The present invention relates to peptides, compositions containing such peptides, and the use thereof. The peptides derived from C-krox binding sequences of three zinc finger domains are effective for stimulating the collagen synthesis of normal human dermal fibroblast, and thus can be used to improve the appearance of the skin. | 04-15-2010 |
| 20100093638 | TREAMENT FOR CHEMICAL SUBSTANCE ADDICTION - The present invention provides a method for the treatment of chemical substance abuse by selectively inhibiting ghrelin activity in humans comprising administering to a human in need thereof a therapeutically-effective amount of a ghrelin receptor ligand (GHS-RL). The ghrelin receptor ligand (GHS-RL) can be selected from the group consisting of a ghrelin receptor antagonist (GHS-RA), a ghrelin receptor inverse agonist (GHS-RIA), and a ghrelin receptor partial agonist (GHS-RPA). More specifically, the invention provides a method for treating alcohol related disorders in humans comprising administering to a human in need thereof a therapeutically-effective amount of a compound which is a ghrelin receptor ligand (GHS-RL), such as a ghrelin receptor antagonist (GHS-RA), a ghrelin receptor inverse agonist (GHS-RIA) and a ghrelin receptor partial agonist (GHS-RPA). | 04-15-2010 |
| 20100093639 | Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides - This invention relates to novel transport molecules that comprise a polypeptide comprising amino acid residues arranged in a sequence that is the reverse-sequence of basic portion of the HIV-TAT protein. The novel transport polypeptides are useful for transmembrane or intracellular delivery of cargo molecules, non-limiting examples of which include polypeptides and nucleic acids. The novel transport polypeptides may be covalently or non-covalenty bound to the cargo molecules. | 04-15-2010 |
| 20100093640 | ACE-INHIBITORY PEPTIDES FROM WHEY AND METHODS FOR PROVIDING THE SAME - The invention relates to methods for providing compounds having an antihypertensive effect. More in particular, the invention relates to ACE (angiotensin I-converting enzyme)-inhibitory peptides that can be released enzymatically from whey proteins. Provided is a method for providing a protein hydrolysate having ACE-inhibitory activity, comprising treating a whey protein-containing substrate with a bacterial heat-labile neutral protease to produce a primary hydrolysate and treating said primary hydrolysate with a thermolysin to produce a secondary hydrolysate. Also provided are hydrolysates and isolated peptides obtainable by said method and uses thereof for the preparation of a medicament for inhibiting ACE activity in a mammal; for lowering the blood pressure; and/or for preventing the occurrence of hypertension. | 04-15-2010 |
| 20100105626 | Novel Analogues of Antimicrobial and Anticancer Peptide Synthesized and Produced from Gaegurin 5 - The present invention is related to antimicrobial and anticancer peptide engineering using Gaegurin 5 isolated from Korean frog ( | 04-29-2010 |
| 20100120696 | Peptides Having Activities of Epidermal Growth Factor and Its Uses - The present invention relates to peptides comprising the amino acid sequence represented by the following formula 1 and having the activities of epidermal growth factor and their uses: Cys-Met-Tyr-Ile-Glu-Linker-Arg-Gly-Asp (1) The EGF-mimicking peptides of the present invention possess identical functions or activities to natural-occurring human EGF and are able to promote the generation of autocrine EGF in cells. In addition the peptides of the present invention are much higher stability and skin penetration potency than natural-occurring EGF. Therefore, the composition containing the peptide exhibits excellent treatment and prevention efficacies on diseases or conditions demanding EGF activities, and can be advantageously applied to pharmaceutical compositions, quasi-drugs and cosmetics. | 05-13-2010 |
| 20100130433 | Casein-Derived Peptides having Anxiolytic Activity - The invention relates to peptides and, in particular, heptapeptides derived from milk casein α | 05-27-2010 |
| 20100137224 | METHOD OF REDUCING INJURY TO MAMMALIAN CELLS - A method of inhibiting the binding between N-methyl-D-aspartate receptors and neuronal proteins in a neuron the method comprising administering to the neuron an effective inhibiting amount of a peptide replacement agent for the NMDA receptor or neuronal protein interaction domain that effect said inhibition of the NMDA receptor neuronal protein. The method is of value in reducing the damaging effect of injury to mammalian cells. Postsynaptic density-95 protein (PSD-95) couples neuronal N-methyl-D-aspartate receptors (NMDARs) to pathways mediating excitotoxicity and ischemic brain damage. This coupling was disrupted by transducing neurons with peptides that bind to modular domains on either side of the PSD-95/NMDAR interaction complex. This treatment attenuated downstream NMDAR signaling without blocking NMDAR activity, protected cultured cortical neurons from excitotoxic insults and dramatically reduced cerebral infarction volume in rats subjected to transient focal cerebral ischemia. The treatment was effective when applied either before, or one hour after, the onset of excitotoxicity in vitro and cerebral ischemia in vivo. This approach prevents negative consequences associated with blocking NMDAR activity and constitutes practical therapy for stroke. | 06-03-2010 |
| 20100144643 | Polymeric Biosufactants - The present invention is directed to biosurfactants that can self-assemble or auto-aggregate into polymeric micellar structures and their use in topically-applied dermatologic products. The invention relates in particular to polymeric acylated biosurfactants (PABs) conforming to the formula Acyl-AA-Term where Acyl is an 8- to 22-membered carbon chain, branched or unbranched, saturated or unsaturated, AA is a consecutive sequence of four to nine amino acid residues, where at least one, preferably at least two of the amino acid residues is charged, and Term is an acid C-terminus or an amide C-terminus. PABs of the present invention have low critical micelle concentrations (predominantly less than about 100 ppm) in an aqueous environment of Minimal Essential Media (MEM) and can lower the surface tension in the aqueous MEM environment to less about 50 dynes/cm2. They also have the ability to increase metabolic soluble proteins. | 06-10-2010 |
| 20100144644 | METAL-BINDING COMPOUNDS AND USES THEREFOR - The invention provides a method of reducing the damage done by reactive oxygen species (ROS) in an animal. The invention also provides a method of reducing the concentration of a metal in an animal. These methods comprise administering to the animal an effective amount of a metal-binding compound as further described in the application. The invention further provides a method of reducing the damage done by ROS to a cell, a tissue or an organ that has been removed from an animal. This method comprising contacting the cell, tissue or organ with a solution or medium containing an effective amount of a metal-binding compound of the invention. The invention further provides novel metal-binding compounds, pharmaceutical compositions comprising the metal-binding compounds, and kits comprising a container holding a metal-binding compound of the invention. | 06-10-2010 |
| 20100160240 | TREATMENT FOR EPILEPSY - The invention provides methods of treating a patient having epilepsy in which an effective regime of an agent that inhibits specific binding of PSD-95 to an NMDA receptor is administered to a patient. | 06-24-2010 |
| 20100168034 | PEPTIDE HAVING CELL MEMBRANE PENETRATING ACTIVITY - The present invention provides a peptide having cell membrane penetrating activity, a transmembrane carrier comprising the peptide having cell membrane penetrating activity as an effective component, a transmembrane complex consisting of the peptide having cell membrane penetrating activity combined with a target substance, a transfection kit comprising the peptide having cell membrane penetrating activity and the target substance, use of the peptide having cell membrane penetrating activity for the manufacture of a transmembrane complex, use of the transmembrane complex for the manufacture of a medicament, and a method for delivering a target substance into cell interior which comprises administrating to a subject with a transmembrane complex consisting of the peptide having cell membrane penetrating activity combined with a target substance to induce transduction of the transmembrane complex into cell interior. The peptide having cell membrane penetrating activity of the present invention has a prominent penetrating efficiency as compared with the activities of prior TAT-derived peptides and so the peptide has applications on intracellular delivery in various research fields as well as on therapeutics of specific diseases where targeting of drugs is required at high efficiency. Accordingly, the peptide having cell membrane penetrating activity, the transmembrane complex consisting of the peptide combined with a target substance and the method for delivering a target substance into cell interior using the transmembrane complex of the present invention are very useful as drug delivery systems. | 07-01-2010 |
| 20100168035 | SUBCUTANEOUS IMPLANTS CONTAINING A DEGRADATION-RESISTANT POLYLACTIDE POLYMER - The present invention refers to compositions comprising a LH-RH-analogue and/or pharmaceutically acceptable salts thereof in a low-dose and a degradation-resistant polylactide suitable for the preparation of subcutaneous implants. Sterilisation of the polylactide via gamma-radiation as well as temperature stress result in a negligible decomposition of less than 1000 Dalton. | 07-01-2010 |
| 20100168036 | GROWTH FACTOR - The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer. | 07-01-2010 |
| 20100173850 | Improved Peptide Composition - A peptide sequence of the form: X(Lys,Arg)XXXXX(Arg,Lys)X, wherein Lys and Arg arc replaceable and X is preferably one or more of the following amino acids: hydrophobic amino acid residues (eg Pro, Leu. Met, Ile), basic amino acid residues or threonine; and wherein the sequence is capable of engaging Λβ and ameliorating its SOD activity and/or metal ion binding. | 07-08-2010 |
| 20100184699 | Peptide Derived From Prostate-Related Protein As Cancer Vaccine Candidate For Prostate Cancer Patient Who Is Positive For Hla-A3 Super-Type Allele Molecule - According to the present invention, a peptide, which is a prostate-related protein derived peptide, capable of binding to an HLA-A3 supertype allele and recognized by the cellular and/or humoral immune system is provided. The peptides of the present invention make feasible the peptide-based anti-cancer vaccine therapy for prostate cancer patients with HLA-A3 supertype allele and useful for the treatment of prostate cancer patients with alleles other than HLA-A2 and -A24 to which cancer vaccine peptide candidates had been identified. | 07-22-2010 |
| 20100184700 | PREPROCALCITONIN ANTIGEN T EPITOPES - The present invention is related to Preprocalcitonin antigen T epitopes, presented by the Major Histocompatibility Complex I (MHC I). These peptides can be used in cancer immunotherapy. | 07-22-2010 |
| 20100190721 | PEPTIDE WHITENING AGENTS AND COSMETIC COMPOSITIONS COMPRISING THE SAME - The present invention relates to novel peptide compounds having the following formula [R | 07-29-2010 |
| 20100190722 | SUBSTANCE P AND THYROTROPIN RELEASING HORMONE FOR THERAPEUTIC APPLICATIONS - The present invention is directed to the use of the peptide compound Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH | 07-29-2010 |
| 20100197603 | USE OF RGDSPASSKP AND OPTIONALLY ANGIOTENSIN II AS THERAPEUTIC AGENTS IN THE TREATMENT OF EG S. PNEUMONIAE INFECTIONS - The present invention is directed to the use of the peptide compound Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys-Pro-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys-Pro-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 08-05-2010 |
| 20100204138 | USE OF TRP6-TRIPTORELIN AND D-LEU6-LEUPROLIDE AS THERAPEUTIC AGENTS - The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pyr-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-NH | 08-12-2010 |
| 20100204139 | USE OF GONADORELIN AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH | 08-12-2010 |
| 20100204140 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH | 08-12-2010 |
| 20100204141 | USE OF BPP-B AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Pyr-Gly-Leu-Pro-Pro-Arg-Pro-Lys-Ile-Pro-Pro-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pyr-Gly-Leu-Pro-Pro-Arg-Pro-Lys-Ile-Pro-Pro-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 08-12-2010 |
| 20100204142 | USE OF THE PEPTIDE PHPFHLFVY (RENIN INHIBITOR) AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Pro-His-Pro-Phe-His-Leu-Phe-Val-Tyr-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pro-His-Pro-Phe-His-Leu-Phe-Val-Tyr-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 08-12-2010 |
| 20100204143 | GAMMA 1 MSH ALONE OR IN COMBINATION WITH PENTAGASTRIN AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-NH | 08-12-2010 |
| 20100204144 | USE OF THE PEPTIDES MAIPPKKNQDK (COW KAPPA CASEIN 106-116) AND/OR YGFQNA (SERORPHIN) AS THERAPEUTIC AGENTS - The present invention is directed to the use of the peptide compound Met-Ala-Ile-Pro-Pro-Lys-Lys-Asn-Gln-Asp-Lys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Met-Ala-Ile-Pro-Pro-Lys-Lys-Asn-Gln-Asp-Lys-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 08-12-2010 |
| 20100204145 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pyr-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 08-12-2010 |
| 20100204146 | Treatment of Oestrogen Dependant Conditions in Pre-menopausal Women - The present invention relates to a method for treating and/or preventing ovarian cycle disturbance, prolonged un-opposed secretion of estrogens, and/or ovarian follicular cyst formation in pre-menopausal women with functional ovaries when treated with steroid sulfatase inhibitors (STS-I) for an estrogen-dependant condition. | 08-12-2010 |
| 20100210561 | USE OF PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Tyr-D-Cys(tBu)-Gly-Phe-Leu-Thr(tBu)-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Tyr-D-Cys(tBu)-Gly-Phe-Leu-Thr(tBu)-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 08-19-2010 |
| 20100210562 | USE OF IL-1 RECEPTOR PEPTIDE, ALONE OR IN COMBINATION WITH D-ALA-GLN-OCTADECYL ESTER, AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Lys-lle-Cys-lle-Arg-lle-Gln-lle-Ser-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Lys-lle-Cys-lle-Arg-lle-Gln-lle-Ser-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 08-19-2010 |
| 20100216723 | NEUROPROTECTION USING NAP-LIKE AND SAL-LIKE PEPTIDE MIMETICS - This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disease. | 08-26-2010 |
| 20100234303 | AGENTS, METHODS AND USES - The present invention relates to agents, compositions and methods for use in medicine. In particular, the invention relates to agents related to GnRH peptides. | 09-16-2010 |
| 20100234304 | BETA SHEET TAPES RIBBONS IN TISSUE ENGINEERING - There is described a material comprising tapes, ribbons, fibrils or fibres characterized in that each of the ribbons, fibrils or fibres have an antiparallel arrangement of peptides in a β-sheet tape-like substructure. | 09-16-2010 |
| 20100234305 | POLYMERIC DELIVERY FORMULATIONS OF LEUPROLIDE WITH IMPROVED EFFICACY - The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate. | 09-16-2010 |
